|Bid||130.15 x 300|
|Ask||132.75 x 300|
|Day's Range||131.38 - 133.82|
|52 Week Range||109.32 - 137.08|
|PE Ratio (TTM)||22.29|
|Dividend & Yield||3.36 (2.48%)|
|1y Target Est||N/A|
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Johnson & Johnson with the following peers – Merck & Co., Inc., Pfizer Inc., Novartis AG Sponsored ADR, Sanofi Sponsored ADR, Stryker Corporation, Medtronic plc, Roche Holding Ltd Genusssch., Eli Lilly and Company, Abbott Laboratories and GlaxoSmithKline plc Sponsored ADR (MRK-US, PFE-US, NVS-US, SNY-US, SYK-US, ... Read more (Read more...)
Analysts expects weakness to drag down its profits and sales below the industry average.
Karyopharm's (KPTI) selinexor reduced the risk of progression or death in previously treated patients with advanced dedifferentiated liposarcoma.